Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sepracor to acquire Oryx Pharma
Under the terms of the agreement, Oryx’s shareholders will receive $50 million and may become entitled to receive subsequent payments up to $20 million upon accomplishment of various
Under the terms of the agreement, Oryx’s shareholders will receive $50 million and may become entitled to receive subsequent payments up to $20 million upon accomplishment of various
The trial will evaluate the safety and efficacy of single-agent carfilzomib in patients with recurrent or advanced solid tumors. Subjects will be enrolled and stratified according to disease
CollaRx Gentamicin Topical is currently under investigation for the treatment and prevention of diabetic foot infections of varying severity in a series of multi-centered Phase II clinical trials.
Mr Mulder replaces interim CFO Frederick Capallo, who will continue to serve as corporate controller. Mulder will report directly to CEO Jake St Philip. For the last two
The AZ-002 Phase IIa clinical trial is an in-clinic proof of concept study. It is a four-center, randomized, double-blind, placebo-controlled evaluation of 49 patients with panic disorder. The
The US multi-center conjunctival allergen challenge study evaluated the onset and duration of effect of two Bepreve concentrations in 130 patients with a history of ocular allergies. Both
The patent application encompasses formulations and compounds that can be instrumental in the development of efficient intradermal vaccines. Alexander Andrianov, Apogee’s vice president of R&D, said: “The new
Under the agreement, Beckman Coulter can develop, manufacture and sell a quantitative viral load hepatitis C virus (HCV) blood test for use on the company’s molecular diagnostic instrument,
The company intends to use the proceeds to further advance its deuterium chemistry platform and product pipeline. The financing was led by a public equity institutional investor and
The collaboration will focus on characterizing interleukin-4 receptors on various human tumors, determining the mechanism of up regulation of these receptors, developing assays and animal models to evaluate